M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes Pharmaceutical TechnologyTerremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.M&A / DealsOncologyRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaceutical Technology Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity. M&A / DealsOncologyRead full story Post navigation Previous: Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy studyNext: Most patients “won’t see benefit” with Alzheimer’s drugs Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
